The HLA system: An update and relevance to patient-donor matching strategies in clinical transplantation

Vox Sanguinis

Volumn 71, Issue 1, 1996, Pages 6-12

  Howell, W Martin ^a,c   Navarrete, Cristina ^b  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^b North London Blood Transfusion Centre   (United Kingdom)

^c SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Clinical transplantation; Graft rejection; GVHD; HLA

Indexed keywords

BONE MARROW TRANSPLANTATION; HLA MATCHING; HLA SYSTEM; HLA TYPING; HUMAN; IMMUNOGENETICS; MAJOR HISTOCOMPATIBILITY COMPLEX; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW;

EID: 0029901547     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1423-0410.1996.7110006.x     Document Type: Review

References (44)

1. Bodmer JG, Marsh SGE, Albert ED, Bodmer WF, Dupont B, Erlich HA, Mach B, Mayr WR, Parham P, Sasazuki T, Schreuder GMTh, Strominger JL, Svejgaard A, Terasaki PI: Nomenclature for factors of the HLA system, 1995. Hum Immunol 1995;43:149-164.
2. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC: Structure of the human class I histocompatibility antigen, HLA-A2. Nature 1987;329:506-512.
3. Stern LJ, Wiley DC: Antigenic peptidc binding by class I and class II histocompatibility proteins. Structure 1994;2:245-251.
4. Parham P: Typing for class I HLA polymorphism: Past, present and future. Eur J Immunogen 1992;19:347-359.
5. Brown JH, Jardetsky TS, Gorga JC, Stern LJ, Urban RG, Strominger JL, Wiley DC: Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 1993; 364:33-39.
6. Le Bouteiller P: HLA class I chromosomal region, genes and products: Facts and questions. Crit Rev Immunol 1994;14:89-129.
7. van der Ven K, Ober C: HLA-G polymorphism in African Americans. J Immunol 1994;153: 5628-5633.
8. Schmidt CM, Orr HT: Maternal/Fetal interactions: The role of the MHC class I molecule HLA-G. Crit Rev Immunol 1993;13:207-224.
9. Trowsdale J, Hanson I, Mockridge I, Beck S, Townsend A, Kelly A: Sequences encoded in the class II region of the MHC related to the 'ABC' superfamily of transporters. Nature 1990;348:741-744.
10. Glynne R, Powis SH, Beck S, Kelly A, Kerr L-A, Trowsdale J: A proteasome-related gene between the two ABC transporter loci in the class II region of the human MHC. Nature 1991;353:357-360
11. Spies T, Bresnahan M, Bahrain S, Arnold D, Blanck G, Mellins E, Pious D, DeMars R: A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway. Nature 1990; 348:744-747.
12. Deverson EV, Cow IR, Coadwell WJ, Monaco JJ, Butcher GW, Howard JC: MHC class II region encoding proteins related to the multidrug resistance family of transmembrane transporters. Nature 1990;348:738-740.
13. Brown MG, Driscoll J, Monaco JJ: Structural and serological similarity of MHC-linked LMP and proteasome (multicatalytic proteinase) complexes. Nature 1991;353:355-357.
14. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, Hwang D, Goldberg AL: Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994;78:761-771.
15. Driscoll J, Brown M, Finley D, Monaco J: MHC-linked LMP gene products specifically alter peptidase activities of the proteasome. Nature 1993;365:262-264.
16. Momburg F, Neefjes JJ, Hammerling GJ: Peptide selection by MHC-encoded TAP transporters. Curr Opin Immunol 1994;6:32-37.
17. Kelly AP, Monaco JJ, Cho S, Trowsdale J: A new human HLA class II-related locus, DM. Nature 1991;353:571-573.
18. Sant AJ, Miller J: MHC class II antigen processing: Biology of invariant chain. Curr Opin Immunol 1994;6:57-63.
19. Morris P, Shaman J, Attaya M, Amaya M, Goodman S, Bergman C, Monaco JJ, Mellins E: An essential role for HLA-DM in antigen presentation by class II major histocompatibility molecules. Nature 1994;368:551-554.
20. Fling SP, Arp B, Pious D: HLA-DMA and -DMB genes are both required for MHC class II/peptide complex formation in antigen-presenting cells. Nature 1994;368:554-558.
21. Sloan VS, Cameron P, Porter G, Gammon M, Amaya M, Mellins E, Zaller DM: Mediation by HLA-DM of dissociation of peptides from HLA-DR. Nature 1995;375:802-806.
22. Engelhard VH: How cells process antigens. Sci Am, August 1994, pp 44-51.
23. Thorsby E, Ronningen KS: Role of HLA genes in predisposition to develop insulin-dependent diabetes mellitus. Ann Med 1992;24:523-531.
24. Patel R, Mickey MR, Terasaki PI: Serotyping for homotransplantation. XVI, Analysis of kidney transplants from unrelated donors. N Engl J Med 1968;279:501-506.
25. Cecka JM, Terasaki PI: The UNOS Scientific Renal Transplant Registry; in Terasaki PI (ed): Clinical Transplants. Los Angeles, UCLA Tissue Typing Laboratory, 1991, pp 1-11.
26. Opelz G: Collaborative Transplant Study - 10 year report. Transplant Proc 1992;24:2342-2355.
27. Takemoto S, Terasaki PI, Cecka JM, Cho YW, Gjertson DW: Survival of nationally shared, HLA-matched kidney transplants from cadaveric donors. N Engl J Med 1992;327:834-839.
28. Opelz G, Mytilineos J, Scherer S, Dunckley H, Trejaut J, Chapman J, Middleton D, Savage D, Fischer O, Bignon J-D, Bensa J-C, Albert E, Norren H for the CTS: Survival of DNA HLA-DR typed and matched cadaver kidney transplants. Lancet 1991;338:461-463.
29. Opelz G: Collaborative Transplant Study - The benefit of exchanging donor kidneys among transplant centers. N Engl J Med 1988;318: 1289-1292.
30. Beatty PG: Results of allogeneic bone marrow transplantation with unrelated or mismatched donors. Semin Oncol 1992;19:13-19.
31. Kernan NA, Bartsch G, Ash RC, Beatty PG, Champlin R, Filipovich A, Gajewski J, Hansen JA, Henslee-Downey J, McCullough J, McGlave P, Perkins HA, Phillips GL, Sanders J, Stroncek D, Donnall Thomas E, Blume KG: Analysis of 462 transplantations from unrelated donors facilitated by the National Bone Marrow Donor Program. N Engl J Med 1993;328:593-602.
32. Davies SM, Ramsay NKC, Haake RJ, Kersey JH, Weisdorf DJ, McGlave PB, Blazar BR: Comparison of engraftment in recipients of matched sibling or unrelated donor marrow allografts. Bone Marrow Transplant 1994;13:51-57.
33. Beatty PG, Clift RA, Mickelson EM, Nisperos BB, Flournoy N, Martin PJ, Sanders JE, Stewart P, Buckner CD, Storb R, Thomas ED, Hansen JA: Marrow transplantation from other than HLA-identical siblings. N Engl J Med 1985; 313:765-771.
34. Kernan NA, Bordignon C, Heller G, Cunningham I, Caytno-Malaspina H, Shank B, Flomenberg N, Burns J, Yang SY, Black P, Collins NH, O'Reilly RJ: Graft failure after T-cell depleted human leukocyte antigen identical marrow transplants for leukemia. I. Analysis of risk factors and results of second transplants. Blood 1989;74:2227-2236.
35. Schattenberg A, Dewitte T, Preijers F, Raemaekers J, Muus P, van der Lely N, Boezeman J, Wessels J, van Dijk B, Hoogenhoul J, Haanen C: Allogeneic bone marrow transplantation for leukemia with marrow grafts depleted of lymphocytes by counterflow centrifugation. Blood 1990;75:1356-1363.
36. O'Reilly RJ, Keever CA, Small TN, Brochstein J: The use of HLA non-identical T cell-depleted marrow transplants for the correction of severe combined immunodeficiency disease. Immunodefic Rev 1989;1:273-309.
37. Oudshoorn M, van Leewen A, vd Zanden HGM, van Rood JJ on behalf of the Editorial Board of BMDW: Bone Marrow Donors Worldwide: A successful exercise in international cooperation. Bone Marrow Transplant 1994;14: 3-8.
38. Vilmer E, Sterkers G, Rahimy C, Denamur E, Elion J, Broyart A, Lescoeur B, Tiercy JM, Gerota J, Blot P: HLA-mismatched cord-blood transplantation in a patient with advanced leukemia. Transplantation 1992;53:1155-1157.
39. Kaminski E, Hows J, Man S, Brookes P, Mackinnon S, Hughes T, Avakian O, Goldman JM, Batchelor JR: Prediction of graft versus host disease by frequency analysis of cytotoxic T cells after unrelated donor bone marrow transplantation. Transplantation 1989;48:608-613.
40. Fussell ST, Donnellan M, Cooley MA, Farrell C: Cytotoxic T lymphocyte precursor frequency does not correlate with either the incidence or severity of graft-versus-host disease after matched unrelated donor bone marrow transplantation. Transplantation 1994;57:673-676.
41. Schwarer AP, Jiang YZ, Deacock S, Brookes PA, Barrett AJ, Goldman JM, Batchelor JR, Lechler RI: Comparison of helper and cytotoxic antirecipient T cell frequencies in unrelated bone marrow transplantation. Transplantation 1994;58:1198-1203.
42. Bishara A, Brautbar C, Nagler A, Slavin S, Lasham B, Cohen I, Kedar E: Prediction by a modified mixed leukocyte reaction assay of graft-versus-host disease and graft rejection after allogeneic bone marrow transplantation. Transplantation 1994;57:1474-1479.
43. Johnsen HE, Beatty PG, Michelson E, Hansen JA, Thomas ED: Donor alloreactivity may predict acute graft-versus-host disease in HLA-matched bone marrow transplantation for leukemia in early remission. Eur J Haematol 1992; 48:249-253.
44. Smyth LA, Witt CS, Christiansen FT, Hermann RP, Hollingsworth PN, Townend DC, Edward E, Dawkins RL: The MHC influences acute graft versus host disease in MHC matched adults undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 1993; 12:351-355.